Gilead Under Fire for Not Selling HIV Drug Lenacapavir to

Gilead Sciences faces intensifying criticism over its refusal to supply lenacapavir, a revolutionary long-acting HIV prevention injection, directly to Médecins Sans Frontières (MSF) for deployment across sub-Saharan Africa. The dispute reveals a fundamental tension between pharmaceutical profit models and global health equity—one with serious implications for European investors betting on African healthcare expansion.

Lenacapavir represents a genuine breakthrough. Administered as a twice-yearly injection, it offers >99% efficacy in preventing HIV infection, far exceeding oral PrEP alternatives like tenofovir. For African markets where adherence to daily medication remains challenging due to stigma, logistics, and healthcare infrastructure gaps, this is transformative technology. MSF's request to source the drug directly—to dramatically reduce costs and accelerate access in resource-limited settings—is clinically and ethically sound.

Gilead's refusal isn't arbitrary; it reflects a calculated commercial strategy. The company has licensed lenacapavir through tiered pricing models to select generic manufacturers in low-income countries, while maintaining premium pricing in higher-income markets. This approach protects revenue streams in wealthier regions while appearing to address equity. However, MSF's inability to negotiate direct supply suggests Gilead prioritizes controlling distribution channels and price floors over maximizing public health impact. The pharmaceutical giant fears that aggressive NGO-led pricing could undermine future pricing power across African markets.

For European investors, this creates a dual-risk scenario. First, there's reputational and regulatory risk. The EU and individual European governments increasingly scrutinize pharma ESG commitments. Gilead's stance attracts political pressure that could translate into unfavorable drug pricing policies, tax incentives withdrawal, or regulatory friction in EU markets. Novartis and GSK, by contrast, have cultivated more collaborative relationships with global health organizations—a competitive advantage in an era where corporate responsibility directly impacts market access.

Second, there's a market structure risk. Gilead's guardedness over direct supply channels suggests confidence in long-term pricing power, but this assumption weakens as African healthcare systems mature and generics proliferation accelerates. Generic lenacapavir manufacturing will eventually commoditize the drug; Gilead's current posture merely delays generic competition while eroding goodwill. European healthcare investors targeting African expansion should note: jurisdictions where pharma companies resist transparent pricing and NGO partnerships tend to face more aggressive regulatory pressure down the line.

The broader implication: African HIV prevention is moving from scarcity to abundance. The real competitive battleground isn't supply; it's trust and institutional relationships. MSF, UNAIDS, and national governments will remember which companies cooperated during the access phase and which prioritized margin protection. For European investors in African diagnostics, digital health, or healthcare delivery, alignment with access principles isn't just ethical—it's a commercial hedge against future policy headwinds.